Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer

ABSTRACT: Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer

PROVIDER: PRJNA1327215 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer

Project description:To characterize the tumor microenvironment (TME) of recurrence-stage high-grade serous ovarian cancer (HGSC) at the single cell level, we performed single-cell RNA sequencing (scRNA-seq) for a total of four samples from three patients. This data set includes scRNA-seq read count data and cell type annotations for each sample.

2025-09-15 | GSE307725 | GEO

AVA-ADR-001- a small molecular inhibitor of ADAR1 (Immuno-oncology target)

Project description:AVA-ADR-001- a small molecular inhibitor of ADAR1 (Immuno-oncology target)

| PRJNA954781 | ENA

Molecular and functional landscape of malignant serous effusions for precision oncology

Project description:Molecular and functional landscape of malignant serous effusions for precision oncology

| PRJNA1005925 | ENA

Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_baseline]

Project description:Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells. These patients frequently develop malignant serous effusions (MSE). The value of MSE-based tumor cell characterization for guiding precision oncology is, however, currently unclear. Here, we present a comprehensive characterization of a pan-cancer cohort of 150 MSE samples at the cellular, molecular, and functional level. Our integrative analysis reveals dynamic cellular heterogeneity in MSE, and uncovers links between tumor driver mutations and ex vivo growth patterns. Strong concordance between genomic and transcriptional profiles of MSE and their corresponding solid tumors validates their use as a model system for solid tumor biology. We link baseline gene expression patterns to global ex vivo drug sensitivity, and demonstrate that drug-induced transcriptional changes in MSE are highly indicative of compound mode of action. Two case studies exemplify the utility of our approach in investigating acquired resistance to targeted therapy and identifying treatment options for relapsed solid tumors. In summary, our study provides a functional multi-omics view on a pan-cancer MSE cohort and underlines the utility of MSE-based precision oncology.

2024-08-26 | GSE240952 | GEO

Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_drug_treated]

2024-08-26 | GSE240951 | GEO

Molecular and functional landscape of malignant serous effusions for precision oncology

Project description:Personalized treatment for patients with advanced solid tumors critically depends on the deep characterization of tumor cells from patient biopsies. Here, we comprehensively characterize a pan-cancer cohort of 150 malignant serous effusion (MSE) samples at the cellular, molecular, and functional level. We find that MSE-derived cancer cells retain the genomic and transcriptomic profiles of their corresponding primary tumors, validating their use as a patient-relevant model system for solid tumor biology. Integrative analyses reveal that baseline gene expression patterns relate to global ex vivo drug sensitivity, while high-throughput drug-induced transcriptional changes in MSE samples are indicative of drug mode of action and acquired treatment resistance. A case study exemplifies the added value of multi-modal MSE profiling for patients who lack genetically stratified treatment options. In summary, our study provides a functional multi-omics view on a pan-cancer solid tumor cohort and underlines the feasibility and utility of MSE-based precision oncology.

2024-10-04 | PXD052582 | Pride

Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_baseline]

Project description:Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_baseline]

| PRJNA1005931 | ENA

Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_drug_treated]

Project description:Molecular and functional landscape of malignant serous effusions for precision oncology [MSE_drug_treated]

| PRJNA1005930 | ENA

Digital Spatial Profiling of immuno-oncology proteins in mouse hepatocellular carcinoma xenograft treated with THIO-based combination immune therapie

Project description:THIO (6-thio-dG) is a nucleoside analog that induces telomeric DNA damage and triggers activation of anti-tumor immunity in several cancer types such as lung and colorectal cancers. To evaluate its effect in hepatocellular carcinoma (HCC), THIO in combination with the current standard care first-line therapy for advanced HCC, anti-PD-L1 and anti-analyze, was tested in immunocompetent mice subcutaneously implanted with syngeneic HCC cell line (Hep55.1c). Formalin-fixed paraffin-embedded (FFPE) tumor tissues were collected after the treatment, and therapeutic modulations of the tumor immune landscape were assessed with Digital Spatial Profiling of 38 immuno-oncology-related proteins in region of interest (ROI) and intra-ROI segments enriched for T cells, other leukocytes, and HCC/stromal cells.

2023-06-07 | GSE219108 | GEO

Oncology

Project description:Oncology Raw sequence reads

| PRJNA1049638 | ENA